Overall world revenue for Contract Research Organisations (CROs) Market, 2023 to 2033 in terms of value will surpass US$68 billion in 2023. The author predicts strong revenue growth through to 2033. The work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
The Contract Research Organisations (CROs) Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The market for biopharmaceuticals is rising, there is an increase in the need for healthcare due to an ageing population, and the biotech, pharmaceutical, and medical device industries are expanding to fulfil this demand. As a result, the demand for effective clinical studies has increased in order to ensure the efficacy and safety of products. Worldwide, there are around 266 thousand open clinical trials ongoing. More than 105,000 open clinical investigations are now being conducted just in the United States.
The burden of uncommon diseases is increasing internationally, which has led to an increase and innovation in the creation of medicines. While it is still true that only a small portion of terminal rare diseases receive their initial treatment each year and that over 90% of these diseases await therapy approval. In 2021, the CDC reported that 475 million individuals, or nearly 10% of the world's population, were thought to be living with a rare disease. 15.2 million Individuals are predicted to receive clinical genetic testing for a rare disease during the course of the next five years. A rising number of nations are putting in place government programs to assist people with rare illnesses.
Additionally, pharmaceutical companies that develop novel medicines are expected to provide clinical data about safety and efficacy to the relevant governmental and regulatory bodies in order for their treatments to be approved. As a result, the guidelines for pre- and post-grant disagreement as well as issues pertaining to the patent are quite strict. However, it improves the efficiency of inspection and has assisted in the cancellation of patents. It is crucial to focus more emphasis on clinical trial agreements since the government thoroughly evaluates clinical trial-related issues as well. However, these issues harm the CRO's reputation and may stop the sector for contract research organisations from expanding.
The Contract Research Organisations (CROs) Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The market for biopharmaceuticals is rising, there is an increase in the need for healthcare due to an ageing population, and the biotech, pharmaceutical, and medical device industries are expanding to fulfil this demand. As a result, the demand for effective clinical studies has increased in order to ensure the efficacy and safety of products. Worldwide, there are around 266 thousand open clinical trials ongoing. More than 105,000 open clinical investigations are now being conducted just in the United States.
The burden of uncommon diseases is increasing internationally, which has led to an increase and innovation in the creation of medicines. While it is still true that only a small portion of terminal rare diseases receive their initial treatment each year and that over 90% of these diseases await therapy approval. In 2021, the CDC reported that 475 million individuals, or nearly 10% of the world's population, were thought to be living with a rare disease. 15.2 million Individuals are predicted to receive clinical genetic testing for a rare disease during the course of the next five years. A rising number of nations are putting in place government programs to assist people with rare illnesses.
Intellectual Property Issues Likely to Challenge Industry Growth
Intellectual property is one of the key barriers to outsourcing clinical trials, which might restrict the expansion of contract research organisations' markets. Because copyrighted products make up the majority of therapeutic candidates, a contract research organisation may increase the danger of data leaks.Additionally, pharmaceutical companies that develop novel medicines are expected to provide clinical data about safety and efficacy to the relevant governmental and regulatory bodies in order for their treatments to be approved. As a result, the guidelines for pre- and post-grant disagreement as well as issues pertaining to the patent are quite strict. However, it improves the efficiency of inspection and has assisted in the cancellation of patents. It is crucial to focus more emphasis on clinical trial agreements since the government thoroughly evaluates clinical trial-related issues as well. However, these issues harm the CRO's reputation and may stop the sector for contract research organisations from expanding.
What Questions Should You Ask Before Buying a Market Research Report?
- How is the contract research organisations (CROs) market evolving?
- What is driving and restraining the contract research organisations (CROs) market?
- How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
- How will the market shares for each contract research organisations (CROs) submarket develop from 2022 to 2033?
- What will be the main driver for the overall market from 2023 to 2033?
- Will leading contract research organisations (CROs) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
- Who are the leading players and what are their prospects over the forecast period?
- What are the contract research organisations (CROs) projects for these leading companies?
- How will the industry evolve during the period between 2023 and 2033? What are the implications of contract research organisations (CROs) projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the contract research organisations (CROs) market?
- Where is the contract research organisations (CROs) market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Contract Research Organisations (CROs) market today, and over the next 10 years:
- Our 353-page report provides 141 tables, 201 charts, and graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2033 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2033, this new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Contract Research Organisations (CROs) prices and recent developments.
Segments Covered in the Report
Service
- Preclinical
- Clinical
- Phase I
- Phase II
- Phase III
- Phase IV
- Laboratory Services
- Consulting Services
- Data Management Services
Company Size
- Large Pharma & Biotech Companies
- Mid-sized Pharma & Biotech Companies
- Small Pharma & Biotech Companies
Drug Type
- Small Molecules
- Large Molecules
Therapeutic Area
- Oncology
- CNS
- Cardiology
- Infectious
- Metabolic
- Other Therapeutic Area
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Switzerland
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Singapore
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
MEA
- GCC
- South Africa
- Egypt
- Rest of MEA
Leading companies and the potential for market growth
- Allucent
- Anthem Biosciences Private Limited
- Bio-Techne
- Charles River Laboratories
- Caidya
- CMIC HOLDINGS Co., Ltd.
- Eurofins Scientific
- Evotec SE
- Frontage Labs
- ICON plc
- Inotiv
- IQVIA Inc.
- Labcorp Drug Development
- Medpace
- Parexel International (MA) Corporation
- PPD (Thermo Fisher Scientific Inc.)
- Syneos Health
- Syngene International Limited
- The Emmes Company, LLC
- Worldwide Clinical Trials
- Wuxi AppTec
How will the Contract Research Organisations (CROs) Market, 2023 to 2033 report help you?
In summary, the 350+ page report provides you with the following knowledge:- Revenue forecasts to 2033 for Contract Research Organisations (CROs) Market, 2023 to 2033, with forecasts for services, company size, drug type, and therapeutic area, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2033 for five regional and 25 key national markets - See forecasts for the Contract Research Organisations (CROs) Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, Singapore, Argentina, GCC, South Africa, and Egypt among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 21 of the major companies involved in the Contract Research Organisations (CROs) Market, 2023 to 2033.
Information found nowhere else
With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how the work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Contract Research Organisations (CROs) Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.Table of Contents
1 Report Overview
3 Market Overview
4 Contract Research Organisations (CROs) Market Analysis by Services
5 Contract Research Organisations (CROs) Market, by Company Size, 2023-2033
6 Contract Research Organisations (CROs) Market, by Drug Type, 2023-2033
7 Contract Research Organisations (CROs) Market, by Therapeutic Area, 2023-2033
8 Contract Research Organisations (CROs) Market Analysis by Region
9 North America Contract Research Organisations (CROs) Market Analysis
10 Europe Contract Research Organisations (CROs) Market, 2023-2033
11 Asia Pacific Contract Research Organisations (CROs) Market Analysis
12 Latin America Contract Research Organisations (CROs) Market Analysis
13 MEA Contract Research Organisations (CROs) Market Analysis
14 Company Profiles
15 Conclusion and Recommendations
List of Tables
List of Figures
Companies Mentioned
- Allucent
- Anthem Biosciences Private Limited
- Bio-Techne
- Charles River Laboratories
- Caidya
- CMIC HOLDINGS Co., Ltd.
- Eurofins Scientific
- Evotec SE
- Frontage Labs
- ICON plc
- Inotiv
- IQVIA Inc.
- Labcorp Drug Development
- Medpace
- Parexel International (MA) Corporation
- PPD (Thermo Fisher Scientific Inc.)
- Syneos Health
- Syngene International Limited
- The Emmes Company, LLC
- Worldwide Clinical Trials
- Wuxi AppTec
- Althian Clinical Research
- AnaBios Corporation
- Avance Clinical
- BenevolentAI
- BioDev Services
- Boehringer Ingelheim
- Care Access
- ClinChoice
- Cognate BioServices, Inc.
- ConcertAI, LLC
- Cypre, Inc.
- Distributed Bio, Inc.
- Ethica CRO
- Explora BioLabs
- Immedica Pharma AB
- JADE Biomedical (JADE)
- Komodo Health
- Matrix Clinical Trials
- Novartis
- Ovia Health
- Retrogenix Limited
- RxDataScience
- StudyKIK
- Toxikon Corporation
- Veeva Systems
- Valo Health, Inc.
- Vigene Biosciences, Inc.
- Xcell Biosciences, Inc.
- Association of British Pharmaceutical Industry (ABPI)
- Association of Clinical Research Organisations (ACRO)
- Central Drugs Standard Control Organisation (CDSCO)
- Development and Reform Commission (NDRC)
- Development Center For Biotechnology (DCB)
- European CRO Federation (EUCROF)
- European Medicines Agency (EMA)
- Food and Drug Administration (FDA)
- Indian Drug Manufacturer's Association (IDMA)
- Indian Society for Clinical Research (ISCR)
- Korea Food and Drug Administration (KFDA)
- Korea Pharmaceutical Manufacturer's Association (KPMA)
- Medicines and Healthcare Products Regulatory Agency (MHRA)
- Medicines Manufacturing Industry Partnership (MMIP)
- Ministry of Health (MOH)
- Ministry of Health, Labour and Welfare (MHLW)
- Pharmaceutical and Medical Devices Agency (PMDA)
- World Health Organization (WHO)